PALO ALTO, Calif., and
CINCINNATI, Ohio, Nov. 19, 2020 /PRNewswire/
-- Varian (NYSE: VAR) and the Cincinnati Children's/UC
Health Proton Therapy Center today announce the start of the first
clinical trial of FLASH therapy as part of the recently opened
FAST-01 study (FeAsibility Study
of FLASH Radiotherapy for the Treatment of
Symptomatic Bone Metastases). The clinical trial involves
the investigational use of Varian's
ProBeam® particle
accelerator modified to enable radiation therapy delivery at
ultra-high dose rates (dose delivered in less than 1 second) and is
being conducted at the Cincinnati Children's/UC Health Proton
Therapy Center with John C. Breneman M.D., Medical Director of
the center, serving as principal investigator.
The first clinical trial patient was treated this week. The
FAST-01 study is expected to enroll up to 10 patients with bone
metastases to evaluate clinical workflow feasibility,
treatment-related side effects, and efficacy of treatment as
assessed by measuring pain relief of trial participants. The
clinical trial, informed by years of preclinical work, was designed
by experts at Varian and multiple centers in the
FlashForwardTM Consortium, including Cincinnati's Children's/UC Health Proton
Therapy Center and the New York Proton Center.
"Treating the first patient in this FLASH clinical trial is
a milestone that many thought was still years ahead of us," said
Kolleen Kennedy, Chief Growth
Officer and President of Proton Therapy Solutions at Varian. "There
was overwhelming support from Dr. Breneman and his team for this
clinical trial, which was designed in collaboration with the
FlashForward Consortium and with significant contributions from the
New York Proton Center. These efforts help Varian safely advance
potential therapy options towards our vision of a world without
fear of cancer."
Breneman noted that, because this is the first in human trial of
FLASH radiotherapy, it will build a foundation for extending this
therapy to other types of cancer treatments.
"Trials using FLASH radiotherapy for lung cancer and other
malignancies are currently being developed," said Breneman, a UC
Health radiation oncologist and a professor emeritus at the
University of Cincinnati College of
Medicine. "Using FLASH treatment for these cancers could deliver
higher cancer-killing doses without causing inordinate side
effects, which would be a real advance."
"FLASH therapy has the potential to be practice changing and
dramatically improve the experience of cancer care for a new
generation of patients. The launch of the first FLASH clinical
trial, a project that has come to fruition after years of intensive
study, is an important milestone in the progress of radiation
therapy," said FlashForward Consortium member Dr. Charles B. Simone, II, FACRO, Chief Medical
Officer at New York Proton Center. "We are optimistic that the
results of the FAST clinical development program will transform the
way the industry approaches treatment. The New York Proton Center
is proud to be a partner in this future-focused study."
John Perentesis, MD, Director of
the Division of Oncology & Cancer Programs at Cincinnati
Children's, said FLASH is potentially a transformational advance
for cancer treatment for many patients."If the side effects of
radiation on the normal tissues surrounding a tumor can be
significantly reduced, the dose of radiation to treat a cancer can
be greatly increased," Perentesis said. "This would raise hope
to cure malignancies that respond to radiation but aren't
completely cured at current doses, including pediatric brain tumors
like DIPG/pontine glioma and medulloblastoma, sarcomas, and
neuroblastoma."
About Varian
At Varian, we envision a world without
fear of cancer. For more than 70 years, we have developed, built
and delivered innovative cancer care technologies and solutions for
our clinical partners around the globe to help them treat millions
of patients each year. With an Intelligent Cancer Care approach, we
are harnessing advanced technologies like artificial intelligence,
machine learning and data analytics to enhance cancer treatment and
expand access to care. Our 10,000 employees across 70 locations
keep the patient and our clinical partners at the center of our
thinking as we power new victories in cancer care. Because, for
cancer patients everywhere, their fight is our fight. For more
information, visit http://www.varian.com and follow
@VarianMedSys on Twitter.
About the Cincinnati Children's/UC Health Proton Therapy
Center
The Cincinnati Children's/UC Health Proton Therapy
Center, which opened in 2016, is one of only 35 in the United States. The Cincinnati center incorporates a $24 million, one-of-a-kind research facility,
which includes a fully operational proton treatment room dedicated
for just research along with integrated laboratories. The unique
capabilities of the research center were instrumental in
Cincinnati developing the world's
first clinical trial of FLASH proton therapy. In addition, children
and adults from around the world seek treatment for more than 30
types of cancer in two clinical therapy rooms at the center.
About New York Proton Center
The New York Proton
Center is creating the gold standard for proton therapy, giving new
hope to patients living with cancer. In partnership with leading
academic medical centers—Memorial Sloan Kettering Cancer Center,
Montefiore Health System, Mount Sinai Health System, and ProHEALTH
as manager—the New York Proton Center brings together expert
oncologists, clinical care teams, and researchers to improve cancer
care and advance the clinical evidence for proton therapy.
About ProBeam®
Varian's ProBeam
proton therapy system is a cancer treatment system that uses
protons rather than X-rays to treat cancerous tumors with great
precision. It is effective for certain types of cancers and can
treat with a high dose of radiation to the tumor, while delivering
lower radiation to the surrounding healthy tissue.
Press
Contacts
|
Investor Relations
Contact
|
Aimee
Corso
Health + Commerce on
behalf of Varian
+1 (310)
780-2661
aimee@healthandcommerce.com
|
Anshul
Maheshwari
Vice President,
Investor Relations
+1 (650)
424-5631
investors@varian.com
|
|
|
Barrett J.
Brunsman
Cincinnati
Children's
Barrett.brunsman@CCHMC.org
|
|
|
|
Nathaniel
Goehring
+1 (781)
608-8437
BerlinRosen on behalf
of NY Proton
Therapy
Center
nathaniel.goehring@berlinrosen.com
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/varian-and-the-cincinnati-childrensuc-health-proton-therapy-center-announce-initial-patient-treated-in-the-fast-01-first-human-clinical-trial-of-flash-therapy-for-cancer-301176678.html
SOURCE Varian